Watch Oncology Clinical Nurse Educators and Real Patients Speak About Jakafi® (ruxolitinib) скачать в хорошем качестве

Watch Oncology Clinical Nurse Educators and Real Patients Speak About Jakafi® (ruxolitinib)

For people living with a rare, chronic blood cancer, finding the right treatment option can be challenging. Listen to people living with polycythemia vera (PV) and certain types of myelofibrosis (MF) taking Jakafi discuss their experiences, providing special insight and information on the everyday issues and important obstacles they face as individuals with rare diseases. This video also features Incyte Oncology Clinical Nurse Educators (OCNEs) providing information about Jakafi and tips on speaking up with your Healthcare Team. Watch now to see these patients talk about their PV and MF journeys. Jakafi® (ruxolitinib) is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also used to treat adults with certain types of myelofibrosis. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your Healthcare Professional for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Incyte and the Incyte logo are registered trademarks of Incyte. Jakafi and the Jakafi logo are registered trademarks of Incyte. © 2022, Incyte. MAT-JAK-03882 09/22 00:04 Chapter 1: Intro 02:12 Chapter 2: PV and MF Background 10:59 Chapter 3: HU Intolerance in PV? 13:59 Chapter 4: Jakafi for PV 17:01 Chapter 5: Jakafi for MF 21:14 Chapter 6: Advice on Patient Advocacy 31:34 Chapter 7: The Importance of Specialized Care 34:51 Chapter 8: Jakafi PV Efficacy Data 44:37 Chapter 9: Long-term Blood Count Data in PV 47:09 Chapter 10: Jakafi MF Efficacy Data 53:20 Chapter 11: MF Long-term Data 58:23 Chapter 12: What to Expect When Taking Jakafi 1:02:43 Chapter 13: IncyteCARES 1:03:32 Chapter 14: Important Safety Information